

## COUNTRY GENERAL INFORMATION (WHO, 2015)

Total population:	32,527,000
Gender F / M (%):	49.3 / 50.7
Population, age group <15/ ≥15 years (%):	47 / 53
Life expectancy at birth (F/M, years) (2015):	62 / 59
GDP (PPP int \$):	2,000
Income status:	Low
Number of 2 <sup>nd</sup> sub-national administrative level divisions, name:	399, District

## EPIDEMIOLOGY



	VL	ACL	ZCL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Non endemic
Number of new cases (incidence):	8	27,787	1,605	N/A
Number of relapses <sup>1</sup> :	No data	375	No data	N/A
<b>Total number of cases</b>	<b>8</b>	<b>28,162</b>	<b>1,605</b>	<b>N/A</b>
Imported cases (#, %):	No data	No data	No data	No data
Gender distribution (% F):	38	50	48	N/A
Age group distribution (% < 5/5-14/>14):	(88/12/0)	(23/40/37)	(42/27/31)	N/A
Incidence rate (cases/10,000 population in endemic areas):	0.06	27.23	13.78	N/A
Number of endemic 2 <sup>nd</sup> sub-national administrative level divisions:	No data	254	16	N/A
Population at risk <sup>2</sup> (% # at risk/total population):	5% 1,606,414/32,527,000	32% 10,340,735/32,527,000	4% 1,164,373/32,527,000	N/A
Was there any outbreak?	No data	No data	No data	N/A
Number of new <sup>3</sup> foci:	No data	No data	No data	N/A

N/A = Not applicable; <sup>1</sup> Relapse in this country is defined as: no definition available; <sup>2</sup> Defined as "Number of people living in 2<sup>nd</sup> sub-national administrative level endemic areas"; <sup>3</sup> Defined as "In this reporting period, an area at the 2<sup>nd</sup> sub-national administrative level reporting cases for the first time ever"



## Monthly distribution of new cases (January-December)

2015	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	1	2	1	1	1	1	1	0	0	0	1	0
ACL	2,407	3,065	2,684	2,934	2,444	2,245	1,391	2,275	1,756	1,938	2,209	2,814
ZCL	116	46	50	35	27	27	18	34	41	362	535	314

VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis




## Incidence rate/10,000 (at the national level) and number of new cases from 1998 to 2015



## Disease distribution of new VL and CL cases at district level per 10,000 population (2015)


### Visceral leishmaniasis



www.who.int/leishmaniasis/Map-VL-Afghanistan-2015.png

The boundaries and names shown and the designations used on these maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.  
Map production: WHO/HIM/NTD/IDM

### Cutaneous leishmaniasis



## CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	2007
Type of surveillance:	Vertical
Is there a vector control programme?	No
Type of insecticide used for Indoor residual Spraying (IRS):	Not available
Year latest national guidelines:	2014
Is leishmaniasis notifiable (mandatory report)?	No
Is there a reservoir host control programme?	No
Number of leishmaniasis health facilities:	23

## DIAGNOSIS

	VL	ACL	ZCL	MCL
Number of people screened actively for:	No data	No data	No data	N/A
Number of people screened passively for:	8	28,162	No data	N/A
Cases diagnosed by RDT* (% , # RDT+/ total VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT* (% , # RDT+/total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam* (parasitology) (% , # slides + / total cases):	100%, (8/8)	No data	No data	N/A
Proportion of positive slides* (% , # slides + / total slides):	100%, (8/8)	No data	No data	N/A
Cases diagnosed clinically* (% , # clinical cases/ total cases):	0%, (0/8)	No data	100% (1,605/1,605)	N/A
Proportion of CL cases with lesions equal to or greater than 4cm*:	N/A	No data	No data	N/A
Proportion of CL cases with 4 or more lesions*:	N/A	no data	No data	N/A
Percentage of cases with HIV coinfection*:	0%, (0/8)	N/A	N/A	N/A

N/A = Not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

## TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? **Yes**
- ▶ Antileishmanial medicines included in the National Medicine List: **Not available**

TREATMENT OUTCOME	VL	ACL	ZCL
Proportion of cases treated*(% , # treated cases/ total cases):	100% (8/8)	100 % (27,787/27,787)	100% (1,605/1,605)
Initial cure rate*(% , # cases initially cured /total cases):	88% (7/8)	No data	No data
Failure rate**(% , # patients with treatment failure /total cases):	0% (0/8)	No data	No data
Case fatality rate*(% , # patients who died/ total cases):	0% (0/8)	No data	No data

VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL= zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis

\* Failure in this country is defined as: no definition available

\*\* These indicators only apply to new cases